ACKR3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL401043	0.51	15/20
SCHEMBL402357	0.51	14/20
SCHEMBL403312	0.51	14/20
SCHEMBL592553	0.48	14/20
SCHEMBL235455	0.45	14/20
SCHEMBL234257	0.49	12/20
SCHEMBL772120	0.36	12/20
SCHEMBL402650	0.48	11/20
SCHEMBL627014	0.63	10/20
SCHEMBL627015	0.61	10/20
SCHEMBL70424	0.51	10/20
SCHEMBL237582	0.46	10/20
SCHEMBL402056	0.54	9/20
SCHEMBL623029	0.51	9/20
SCHEMBL402292	0.49	9/20
SCHEMBL402086	0.51	8/20
SCHEMBL573113	0.49	8/20
SCHEMBL573114	0.49	8/20
SCHEMBL573115	0.49	8/20
SCHEMBL573116	0.49	8/20

Clinical trials — most relevant to ACKR3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)	PHASE4	UNKNOWN
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients	PHASE1/PHASE2	COMPLETED
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis	PHASE2	COMPLETED
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation	PHASE1	RECRUITING
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	PHASE1	RECRUITING
GSK2239633 FTIH Study	PHASE1	COMPLETED
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study	EARLY_PHASE1	RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma	nan	UNKNOWN
Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease	nan	COMPLETED
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE	nan	UNKNOWN
Comparative Study Between Alzheimer's and Multi-infarct Dementia	nan	UNKNOWN
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure	nan	UNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
Inflammatory Biomarkers in Seizure	nan	UNKNOWN
The Effects of Sleeve Gastrectomy on Fractalkine	nan	COMPLETED
Value of Various Chemokines in the Detection and Follow up of RCC	nan	UNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage	nan	ENROLLING_BY_INVITATION
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.	nan	NOT_YET_RECRUITING
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA	nan	RECRUITING
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis	nan	NOT_YET_RECRUITING
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib	nan	COMPLETED
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease	nan	COMPLETED
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.	nan	ENROLLING_BY_INVITATION
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing ThroughMarrow-Blood Barrier	nan	UNKNOWN
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a ACKR3 binder may also engage these)

Protein	Name	Similarity
P11613	—	0.999	P11613 →
O89039	—	0.997	O89039 →
P56485	—	0.993	P56485 →
P35351	—	0.992	P35351 →
P32303	—	0.992	P32303 →
Q9N0Z0	—	0.990	Q9N0Z0 →
P35374	—	0.990	P35374 →
P79785	—	0.989	P79785 →
Q9Z0Z6	—	0.989	Q9Z0Z6 →
P33396	—	0.989	P33396 →
P29754	—	0.987	P29754 →
Q9TSQ8	—	0.987	Q9TSQ8 →
P56412	—	0.987	P56412 →
E9QJ73	—	0.987	E9QJ73 →
Q9BDS8	—	0.986	Q9BDS8 →
P35373	—	0.986	P35373 →
Q0VDU3	—	0.986	Q0VDU3 →
B0UXR0	—	0.985	B0UXR0 →
Q95ND1	—	0.985	Q95ND1 →
Q9BG77	—	0.985	Q9BG77 →
Q2Y2P0	—	0.985	Q2Y2P0 →
O18793	—	0.985	O18793 →
Q9XSD4	—	0.985	Q9XSD4 →
P49685	—	0.985	P49685 →
Q9XT45	—	0.985	Q9XT45 →
O18983	—	0.984	O18983 →
Q28929	—	0.984	Q28929 →
O54814	—	0.984	O54814 →
P51676	—	0.984	P51676 →
P61815	—	0.984	P61815 →